FSI Stanford Publications

Modeling Cost-Effectiveness of Helicobacter pylori Screening to Prevent Gastric Cancer: A Mandate for Clinical Trials

Journal Article

Authors
Julie Parsonnet - Stanford University
Douglas K. Owens - Stanford University
H.H. Hack
Douglas K. Owens - Stanford University

Published by
Lancet, Vol. 348, page(s) 150-154
1996

Publications of interest

Helicobacter pylori and Gastric Cancer: What are the Benefits of Screening Only for the CagA Phenotype of H. pylori?
R.A. Harris, Douglas K. Owens, H. Witherell, Julie Parsonnet
Helicobacter vol. 4 (1999)
Helicobacter pylori and Risk for Gastric Adenocarcinoma
RJ Asghar, Julie Parsonnet
Seminars in Gastrointestinal Disease vol. 3, 12 (2001)
Eradication Rate of Helicobacter pylori in a Mexican Population at High Risk for Gastric Cancer and Use of Serology to Assess Cure
A Mohar, C Ley, J Guarner, R Herrera-Goepfert, L Sanchez Figueroa, D Halperin, Julie Parsonnet
American Journal of Gastroenterology (2002)
Cost-Effectiveness of a Potential Prophylactic Helicobacter pylori Vaccine in the United States.
Rupnow MF, Chang AH, Ross D. Shachter, Douglas K. Owens, Julie Parsonnet
Journal of Infectious Disease vol. 200 (2009)